Treatment Information

Back

Melanoma treatment details. Chemotherapy.

Addenbrooke’s Hospital, Cambridge, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:5City/State/Province:Cambridge
Treatments:ChemotherapyHospital:Addenbrooke’s Hospital
Drugs:Journal:Link
Date:Jan 2010

Description:

Patients:
This study involved 152 patients with metastatic malignant melanoma. The median patient age was 62 years and 54.6% were male.

Treatment:
Patients were treated with the chemotherapy agent lenalidomide.

Toxicities:
There was one treatment-related death due to dyspnea (shortness of breath). Grade 3-4 constipation, nausea, fatigue, diarrhea, and neutropenia were also reported.

Results:
The median overall survival was 5.9 months.

Support:
This study was supported by Celgene, makers of Revlimid (lenalidomide).

Correspondence: Dr. Tim Eisen; email: [email protected]



Back